The company notes the publication of results from a positive phase 1 clinical study in 60 healthy US volunteers using a nasal gel formulation of its lead drug, XF-73 (exeporfinium chloride) in the peer reviewed Journal of Global Antimicrobial Resistance.
The headline results from this study were previously announced by the company on 5 September 2016. The reported US study was independently conducted and sponsored by the National Institute of Allergy and Infectious Diseases, part of the US National Institutes of Health (NIH).
In addition to the study reporting a favourable safety and local tolerability profile of the nasal gel formulation (the primary objective), it also noted as expected that exposure to XF-73 produced a rapid reduction in levels of nasal S. aureus in all subjects.
Neil Clark, Destiny Pharma’s CEO, commented: “We look forward to reporting headline data in mid-2020 from our ongoing 200 patient phase 2b trial that is assessing the ability of XF-73 to reduce nasal levels of S. aureus in patients at high risk of infection that are undergoing surgery.”